Associated Papers
Addition of Trastuzumab Deruxtecan to Selpercatinib in a Patient With RET Fusion-Driven NSCLC and an Acquired HER2 Amplification: Case Report.
Vakkalagadda CV et al.
Jto Clinical and Research Reports, 2023
Select a paper to view details